Li Haolong, Zhang Xinxin, Li Xinyu, Shen Jingnan, Yin Junqiang, Zou Changye, Xie Xianbiao, Huang Gang, Lin Tiao
Department of Musculoskeletal Oncology, The First Affiliated Hospital, Sun Yat-sen University, 58#, Zhongshan 2 Road, Guangzhou 510080, China.
Department of Urology and Andrology, The First Affiliated Hospital, Sun Yat-sen University, 58#, Zhongshan 2 Road, Guangzhou 510080, China.
J Bone Oncol. 2024 Jul 15;47:100623. doi: 10.1016/j.jbo.2024.100623. eCollection 2024 Aug.
BACKGROUND/PURPOSE: This study aimed to summarize the survival and complication profiles of the compress® endoprosthesis (CPS) through a systematic review and -analysis.
Online databases (PubMed, EMBASE and Web of Science) were searched from inception to November 2023. Trials were included that involved the use of CPS for endoprosthetic replacement in patients with massive segmental bone defects. Patients' clinical characteristics and demographic data were extracted using a standardized form. The methodological quality of included 13 non-comparative studies was assessed on basis of the Methodological Index for Non-Randomized Studies (MINORS). All the available Kaplan-Meier curves in the included studies were digitized and combined using Engauge-Digitizer software and the R Project for Statistical Computing.
The -analysis of thirteen included studies indicated: the all-cause failure rates of CPS were 26.3 % after surgery, in which the occurrence rates of aseptic loosening were 5.8 %. And the incidences of other complications were as follows: soft tissue failure (1.8 %), structure failure (8.2 %), infection (9.5 %), tumor progression (1.1 %). The 1-, 4-, and 8-year overall survival rates for all-cause failure with 95 % CI were 89 % (86 %-92 %), 75 % (71 %-79 %) and 65 % (60 %-70 %), respectively. The estimated mean survival time of all-cause failure was 145 months (95 % CI, 127-148 months), and the estimated median survival time of all-cause failure was 187 months (95 % CI, 135-198 months). The 1-, 4-, and 8-year overall survival rates of aseptic loosening with 95 % CI were 96 % (94 %-98 %), 91 % (87 %-95 %) and 88 % (83 %-93 %), respectively. The estimated mean survival time of aseptic loosening was 148 months (95 % CI, 137-153 months).
CPS's innovative spring system promotes bone ingrowth by providing immediate and high-compression fixation, thereby reducing the risk of aseptic loosening caused by stress shielding and particle-induced osteolysis. CPS requires less residual bone mass for reconstructing massive segmental bone defects and facilitates easier revision due to its non-cemented fixation. In addition, the survival rate, estimated mean survival time, and complication rates of CPS are not inferior to those of common endoprosthesis.
背景/目的:本研究旨在通过系统评价和分析总结Compress® 内置假体(CPS)的生存情况和并发症特征。
检索了从建库至2023年11月的在线数据库(PubMed、EMBASE和Web of Science)。纳入了涉及使用CPS进行大块节段性骨缺损患者的内置假体置换的试验。使用标准化表格提取患者的临床特征和人口统计学数据。根据非随机研究方法学指数(MINORS)评估纳入的13项非对照研究的方法学质量。使用Engauge-Digitizer软件和R统计计算项目对纳入研究中所有可用的Kaplan-Meier曲线进行数字化处理并合并。
对纳入的13项研究的分析表明:CPS术后全因失败率为26.3%,其中无菌性松动发生率为5.8%。其他并发症的发生率如下:软组织失败(1.8%)、结构失败(8.2%)、感染(9.5%)、肿瘤进展(1.1%)。全因失败的1年、4年和8年总生存率及95%置信区间分别为89%(86%-92%)、75%(71%-79%)和65%(60%-70%)。全因失败的估计平均生存时间为145个月(95%置信区间,127-148个月),全因失败的估计中位生存时间为187个月(95%置信区间,135-198个月)。无菌性松动的1年、4年和8年总生存率及95%置信区间分别为96%(94%-98%)、91%(87%-95%)和88%(83%-93%)。无菌性松动的估计平均生存时间为148个月(95%置信区间,137-153个月)。
CPS创新的弹簧系统通过提供即时和高压缩固定促进骨长入,从而降低应力遮挡和颗粒诱导骨溶解导致无菌性松动的风险。CPS重建大块节段性骨缺损所需的残余骨量较少,且由于其非骨水泥固定便于更容易翻修。此外,CPS的生存率、估计平均生存时间和并发症发生率不低于普通内置假体。